Total Voting Rights
In accordance with the FSA Disclosure and Transparency Rules, Craneware announces that at the date of this notice its issued share capital comprises 26,987,823 ordinary shares of 1p (“Ordinary Shares”) each with voting rights.
No Ordinary Shares are held in treasury.
The total voting rights in the Company is therefore 26,987,823. The voting rights of all of the Ordinary Shares are identical.
The figure above may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Craneware, under the FSA Disclosure and Transparency Rules.
For further information, please contact:
- +44 (0) 131 550 3100
- Keith Neilson, CEO
- Craig Preston, CFO
- +44 (0) 20 7418 8900
- Dan Webster
- Richard Kauffer
- +44 (0) 20 7653 9850
- Caroline Evans-Jones
- Fiona Conroy
Founded in 1999, Craneware has headquarters in Edinburgh, Scotland with offices in Atlanta, Boston, Nashville and Scottsdale employing over 200 staff. Craneware is the leader in automated revenue integrity solutions that improve financial performance for healthcare organisations. Craneware’s market-driven, SaaS solutions help hospitals and other healthcare providers more effectively price, charge, code and retain earned revenue for patient care services and supplies. This optimises reimbursement, increases operational efficiency and minimises compliance risk. By partnering with Craneware, clients achieve the visibility required to identify, address and prevent revenue leakage. To learn more, visit craneware.com.
The above documents and information on this website are provided to you for informational purposes only and additional information is available on request.None of the documents or information on this website constitute a solicitation, offer,opinion or recommendation to buy or sell any security, or to provide any legal,tax, accounting or investment advice or services regarding the profitability or suitability of any security or investment, nor is it intended for use by, or distribution to, any person or entity in any country or jurisdiction where such use or distribution would be contrary to law or regulation.
Whilst every effort has been taken to ensure that the documents and information on this website are accurate, current, complete, fit for its intended purpose and compliant with the relevant United Kingdom legislation and regulations as at the date of issue, Craneware plc does not warrant that the documents and information on this website are accurate, current, complete, fit for its intended purpose and compliant with the relevant United Kingdom legislation and regulations. In particular,Craneware plc does not warrant that any market data or prices are complete or accurate.
None of the securities of Craneware plc have been nor will they be registered under the US Securities Act of 1933, as amended (the “US Securities Act“) or any relevant securities laws of any state or other jurisdiction of the United States of America or any state, province or territory of Canada, Australia, New Zealand and Japan and may not be offered or sold in the United States of America unless they are registered under the US Securities Act or an exemption from registration is available.
Any opinions or estimates expressed in the documents or on this website may be subject to change without notice and Craneware plc is under no to update its opinions, estimates or other information contained in the documents or on this website. Neither Craneware plc nor any of its affiliates accept any liability whatsoever for any direct or consequential loss arising from any use of any of the documents, their contents, or the contents of this website. Please remember that past performance is not necessarily a guide for future performance. The value of instruments and the income from them can go down as well as up.
In certain jurisdictions viewing the documents and the information on this website may be unlawful or restricted to certain categories of person.If you are not permitted or are in any doubt as to whether you are permitted to view materials on this website, please exit this webpage.
You might also like...
Dec 21, 2018 | Announcements
Strong performance expected to deliver revenue and adjusted EBITDA growth in the range of 15% to 20% 21 December 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, notes the recent...read more
Nov 9, 2018 | Announcements
09 November 2018 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, today gives further information regarding its final dividend announced on 4 September 2018. For those shareholders...read more